Trigger Event Trader

No detailed brain note yet for Trigger Event Trader. USPs will populate as FID mines its promos.

• TOT BIO

  Front-endOld (Inactive)4.0/10
  2026-06-25· Trigger Event Trader· Teases: **Clues given:** - Trades for less than $10 per share (at time of writing, May 2024) - Market cap approximately $2 billion - Recently went public (IPO relatively recent as of 2024) - Ranked by Fortune among top 100 AI companies in 2018 — before going public - Owns the fastest supercomputer in biopharma; ranked near top of TOP500 list globally - 50 petabytes of proprietary biological and chemical data - Executes 2.2 million experiments per week - Uses cell imaging + AI algorithms (morphological profiling / image-based profiling) - Warehouses filled with machines constantly feeding data - Partnership with Roche-Genentech (eligible for up to $3.7B in milestone payments) - Partnership with Bayer (eligible for up to $1.5B in milestone payments) - Partnership with Takeda (eligible for up to $760M in milestone payments) - Largest shareholder: Baillie Gifford & Co. (famous early Tesla and Moderna investor) - Nvidia invested approximately $76M; one of only 5 stocks in Nvidia's portfolio; represents a major portion of Nvidia's 2-stock concentrated portfolio - Has its own proprietary drug pipeline (not just a platform company) - Five clinical trials underway; multiple preclinical projects - Focus areas: neurology, oncology, immunology, rare diseases - Phase 2 trial for cerebral cavernous malformation (CCM) — first drug ever brought to clinical trial found by machine learning - Drug added to drinking water in animal study; "significantly" decreased brain lesions - Phase 1: well-tolerated, no severe side effects; "vast majority" of 62 patients elected to continue into long-term extension - CEO described platform as "Google Street View for cells" — tens of millions of pictures of cells per week - Stock popped as high as 121% in one day on news of Nvidia's initial investment - Nvidia's VP of Healthcare Kimberly Powell specifically cited this company in public statements - Juergen Eckhardt (head of BD at Bayer) quoted about the company's AI methodology **Best prediction:** **Recursion Pharmaceuticals (RXRX)** **Reasoning:** Every clue maps precisely to Recursion Pharmaceuticals. RXRX: (1) traded below $10 in early-mid 2024 with ~$2B market cap; (2) went public via IPO in April 2021; (3) was ranked by Fortune among top 100 AI companies in 2018 pre-IPO; (4) owns the "BioHive-2" supercomputer, one of the most powerful in the world and the most powerful in biopharma, built on Nvidia GPUs (504 H100s added, quadrupling capacity); (5) uses cell imaging + morphological profiling at massive scale; (6) has partnerships with Roche-Genentech, Bayer, and Takeda with exactly the milestone figures cited; (7) Baillie Gifford is its largest institutional shareholder; (8) Nvidia made a $76M strategic investment in RXRX as part of its healthcare AI initiative; (9) has a CCM (cerebral cavernous malformation) program (REC-994) in Phase 2; (10) CEO Chris Gibson used the "Google Street View for cells" analogy publicly; (11) Kimberly Powell and Jensen Huang have both publicly cited Recursion. The stock did pop ~121% on the Nvidia investment announcement in May 2023. **Confidence level: High** — This is an unambiguous identification. Every single clue in the copy matches Recursion Pharmaceuticals (RXRX) with no plausible alternative.

  1. Hook Strength: 8/10 — The Nvidia CEO quote as eyebrow combined with "Why Nvidia Is Going All-In on This $10 TechBio Stock" and a specific July 1 date creates immediate, specific curiosity; the $10 price point and the "one out of 6,600 biotechs" framing give a skeptical reader a concrete reason to

• TOT Calendar

  Backend VSLOld (Inactive)3.0/10
  2026-06-16· Trigger Event Trader· Teases: The promo contains multiple partial stock teases within the bonus reports rather than a single primary tease. The named companies (Chevron, Shell, BP, ExxonMobil, Occidental, Woodside) are fully identified for the lease sale trades. The veiled picks are in the bonus reports: **"The Big Beautiful Nation" — Defense/Shipbuilding (4 companies):** *Company 1 (Virginia-class submarines):* - Clues: One of only two companies capable of building Virginia-class attack submarines; Navy wants to grow fleet from 22 to 66; CEO quoted from recent earnings call; $55 billion backlog; 17% average annual gains over 15 years; primary contractor behind the "Golden Fleet" - Best prediction: **HII (Huntington Ingalls Industries)** — the dominant U.S. naval shipbuilder, primary builder of Virginia-class submarines, known for massive Navy backlogs - Confidence: **High** *Company 2 (nuclear reactors — monopoly):* - Clues: No competitors; monopoly on single most critical component of advanced military vessels; $7 billion contracted revenue locked in; 20% per year average over 10 years; 56% gain in 2025; U.S. Navy's sole nuclear reactor supplier - Best prediction: **BWX Technologies (BWXT)** — sole supplier of naval nuclear reactors to the U.S. Navy, no domestic competitors, consistent strong performance - Confidence: **High** *Company 3 (radar systems):* - Clues: $438 million radar contract; replacing all 612 radar systems in the U.S. - Best prediction: **L3Harris Technologies** or **Raytheon (RTX)** — both are major radar system contractors for the U.S. military; the specific $438M contract for 612 systems narrows it but could fit either - Confidence: **Medium** *Company 4 (small-cap defense):* - Clues: Trades at $10; $1.5 billion in cash; expects $375 million revenue this year (up 650% from last year); average analyst price target of $20 - Best prediction: Insufficient information to identify with confidence — the 650% revenue growth and $10 stock price with $1.5B cash is an unusual combination; could be a defense tech or drone company that recently won a large contract - Confidence: **Low** **"The Big Beautiful Industry" — Infrastructure (2 companies):** *Company 1 (automation/instrumentation):* - Clues: Automation and instrumentation for energy operations; Shell, BP, Chevron, ExxonMobil all use their control systems, flow meters, and wellhead automation; profits almost every year for three decades; $1.83B profit in 1996, $3.47B in 2025; EPS up 18%; dividend raised for 68 consecutive years - Best prediction: **Emerson Electric (EMR)** — 68-year dividend growth streak matches exactly (Emerson is a Dividend King); provides automation and instrumentation to oil and gas industry; revenue and profit profile consistent with the figures cited - Confidence: **High** *Company 2 (electrical infrastructure):* - Clues: Builds and maintains electrical infrastructure for offshore platforms, pipelines, data centers, industrial facilities; revenue up 31% last year; net income up 40.7%; EPS up 40%; plans $4.2 billion revenue this year (27% jump) - Best prediction: **MYR Group (MYRG)** or **Quanta Services (PWR)** — Quanta Services fits best given the scale ($4.2B revenue), the electrical infrastructure focus across energy and industrial sectors, and the growth rates cited - Confidence: **Medium-High** (Quanta Services is the stronger candidate given revenue scale)

  1. Hook Strength: 9/10 — The opening discovery sequence (reading 870 pages, finding something on pages 139–144 he "had to read three times to believe," a government-published trading calendar) is a masterclass in curiosity-gap construction that earns continued reading from even the most jaded financ

No emails captured yet (iSpy not connected).